Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
105,841,018
-
Number of holders
-
23
-
Total 13F shares, excl. options
-
2,979,307
-
Shares change
-
+1,301,384
-
Total reported value, excl. options
-
$6,641,000
-
Value change
-
+$1,671,317
-
Put/Call ratio
-
7.8%
-
Number of buys
-
17
-
Number of sells
-
10
-
Price
-
$2.23
Institutional Holders of SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) as of Q2 2022
As of 30 Jun 2022 SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) had 38 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 2,979,307 shares of stock of the company.
Largest 10 holders included Empery Asset Management, LP, VANGUARD GROUP INC, BlackRock Inc., Alyeska Investment Group, L.P., GEODE CAPITAL MANAGEMENT, LLC, Equitable Holdings, Inc., HIGHBRIDGE CAPITAL MANAGEMENT LLC, MORGAN STANLEY, STATE STREET CORP, and CITADEL ADVISORS LLC.
This table shows 38 institutional shareholders of the security as of 30 Jun 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.